18,715 Shares in Tyra Biosciences, Inc. $TYRA Purchased by Walleye Capital LLC

Walleye Capital LLC bought a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 18,715 shares of the company’s stock, valued at approximately $717,000.

A number of other hedge funds have also made changes to their positions in the stock. Hilton Head Capital Partners LLC purchased a new stake in shares of Tyra Biosciences in the first quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new position in Tyra Biosciences during the fourth quarter valued at approximately $51,000. Chung Wu Investment Group LLC acquired a new position in Tyra Biosciences in the 4th quarter valued at approximately $53,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Tyra Biosciences by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after buying an additional 534 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after buying an additional 1,668 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TYRA has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Friday, July 17th. Canaccord Genuity Group began coverage on shares of Tyra Biosciences in a research note on Monday, April 6th. They issued a “buy” rating and a $50.00 price target on the stock. JonesTrading started coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective for the company. Guggenheim assumed coverage on Tyra Biosciences in a research note on Tuesday, April 14th. They issued a “buy” rating and a $54.00 target price on the stock. Finally, Bank of America upped their target price on Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $47.00.

Tyra Biosciences Stock Down 0.6%

NASDAQ TYRA opened at $30.63 on Friday. The stock has a market capitalization of $1.82 billion, a PE ratio of -14.05 and a beta of 0.76. The company has a 50 day moving average price of $30.68 and a two-hundred day moving average price of $32.56. Tyra Biosciences, Inc. has a 12-month low of $9.96 and a 12-month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). As a group, equities analysts anticipate that Tyra Biosciences, Inc. will post -2.68 EPS for the current year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.